Table 2.
Clinical response and adverse reactions after EGFR-TKIs therapy in cohort study
|
BIM deletion status
|
P-value | ||
|---|---|---|---|
| Heterozygous (N=37) |
Wild type (N=103) |
||
| Clinical response, n (%) | |||
| ORR | 16 (48.5) | 63 (63.0) | 0.16 |
| 95% CI | 30.8–66.5 | 52.8–72.4 | |
| DCR | 31 (93.9) | 97 (97.0) | 0.60 |
| 95% CI | 79.8–99.3 | 91.5–99.4 | |
| Any adverse events, n (%) | 18 (48.6) | 55 (53.4) | |
| Rash | 16 (43.2) | 50 (48.5) | |
| Diarrhea | 7 (18.9) | 10 (9.7) | |
| Liver function impaired | 4 (10.8) | 13 (12.6) | |
| Paronychia | 2 (5.4) | 2 (1.9) | |
| Epistaxis | 0 | 3 (2.9) | |
Abbreviations: CI, confidence interval; DCR, disease control rate; EGFR, epidermal growth factor receptor; ORR, objective response rate; TKIs, tyrosine kinase inhibitors.